Serum Prognostic Factors of Androgen-deprivation Therapy among Japanese Men with De Novo Metastatic Prostate Cancer

Research output: Contribution to journalArticle

Abstract

Background/Aim: To date, several serum prognostic factors have been reported in metastatic prostate cancer. In this study, we examined the prognostic value of these serum markers in Japanese men. Patients and Methods: This study included 104 patients with metastatic prostate cancer who were treated with primary androgen-deprivation therapy from 2001 to 2013. Clinicopathological factors including several serum markers were investigated for association with progression-free (PFS) and overall (OS) survival. Results: During a median follow-up of 48.1 months, median PFS and OS were 24.0 months and 67.4 months, respectively. When adjusted by age, prostate-specific antigen at diagnosis, Gleason score, and clinical stage, serum lactate dehydrogenase value was significantly associated with PFS [hazard ratio (HR)=1.42, 95% confidence interval (CI)=1.15-1.74; p=0.0004] and OS (HR=1.46, 95% CI=1.13-1.82; p=0.0014), in addition to alkaline phosphatase value for OS (HR=1.04; 95% CI=1.00-1.07; p=0.015). Conclusion: This study demonstrates the prognostic significance of alkaline phosphatase and lactate dehydrogenase values in Japanese men with de novo metastatic hormone-sensitive prostate cancer.

Original languageEnglish
Pages (from-to)3191-3195
Number of pages5
JournalAnticancer research
Volume39
Issue number6
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Androgens
Prostatic Neoplasms
Confidence Intervals
L-Lactate Dehydrogenase
Alkaline Phosphatase
Biomarkers
Serum
Neoplasm Grading
Prostate-Specific Antigen
Therapeutics
Hormones
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{6174dcd73f88493e9a66879d8bb6d683,
title = "Serum Prognostic Factors of Androgen-deprivation Therapy among Japanese Men with De Novo Metastatic Prostate Cancer",
abstract = "Background/Aim: To date, several serum prognostic factors have been reported in metastatic prostate cancer. In this study, we examined the prognostic value of these serum markers in Japanese men. Patients and Methods: This study included 104 patients with metastatic prostate cancer who were treated with primary androgen-deprivation therapy from 2001 to 2013. Clinicopathological factors including several serum markers were investigated for association with progression-free (PFS) and overall (OS) survival. Results: During a median follow-up of 48.1 months, median PFS and OS were 24.0 months and 67.4 months, respectively. When adjusted by age, prostate-specific antigen at diagnosis, Gleason score, and clinical stage, serum lactate dehydrogenase value was significantly associated with PFS [hazard ratio (HR)=1.42, 95{\%} confidence interval (CI)=1.15-1.74; p=0.0004] and OS (HR=1.46, 95{\%} CI=1.13-1.82; p=0.0014), in addition to alkaline phosphatase value for OS (HR=1.04; 95{\%} CI=1.00-1.07; p=0.015). Conclusion: This study demonstrates the prognostic significance of alkaline phosphatase and lactate dehydrogenase values in Japanese men with de novo metastatic hormone-sensitive prostate cancer.",
author = "Takeshi Kobayashi and Ryo Namitome and Yu Hirata and masaki shiota and Kenjiro Imada and Eiji Kashiwagi and ario takeuchi and Junichi Inokuchi and Katsunori Tatsugami and Masatoshi Eto",
year = "2019",
month = "1",
day = "1",
doi = "10.21873/anticanres.13457",
language = "English",
volume = "39",
pages = "3191--3195",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Serum Prognostic Factors of Androgen-deprivation Therapy among Japanese Men with De Novo Metastatic Prostate Cancer

AU - Kobayashi, Takeshi

AU - Namitome, Ryo

AU - Hirata, Yu

AU - shiota, masaki

AU - Imada, Kenjiro

AU - Kashiwagi, Eiji

AU - takeuchi, ario

AU - Inokuchi, Junichi

AU - Tatsugami, Katsunori

AU - Eto, Masatoshi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/Aim: To date, several serum prognostic factors have been reported in metastatic prostate cancer. In this study, we examined the prognostic value of these serum markers in Japanese men. Patients and Methods: This study included 104 patients with metastatic prostate cancer who were treated with primary androgen-deprivation therapy from 2001 to 2013. Clinicopathological factors including several serum markers were investigated for association with progression-free (PFS) and overall (OS) survival. Results: During a median follow-up of 48.1 months, median PFS and OS were 24.0 months and 67.4 months, respectively. When adjusted by age, prostate-specific antigen at diagnosis, Gleason score, and clinical stage, serum lactate dehydrogenase value was significantly associated with PFS [hazard ratio (HR)=1.42, 95% confidence interval (CI)=1.15-1.74; p=0.0004] and OS (HR=1.46, 95% CI=1.13-1.82; p=0.0014), in addition to alkaline phosphatase value for OS (HR=1.04; 95% CI=1.00-1.07; p=0.015). Conclusion: This study demonstrates the prognostic significance of alkaline phosphatase and lactate dehydrogenase values in Japanese men with de novo metastatic hormone-sensitive prostate cancer.

AB - Background/Aim: To date, several serum prognostic factors have been reported in metastatic prostate cancer. In this study, we examined the prognostic value of these serum markers in Japanese men. Patients and Methods: This study included 104 patients with metastatic prostate cancer who were treated with primary androgen-deprivation therapy from 2001 to 2013. Clinicopathological factors including several serum markers were investigated for association with progression-free (PFS) and overall (OS) survival. Results: During a median follow-up of 48.1 months, median PFS and OS were 24.0 months and 67.4 months, respectively. When adjusted by age, prostate-specific antigen at diagnosis, Gleason score, and clinical stage, serum lactate dehydrogenase value was significantly associated with PFS [hazard ratio (HR)=1.42, 95% confidence interval (CI)=1.15-1.74; p=0.0004] and OS (HR=1.46, 95% CI=1.13-1.82; p=0.0014), in addition to alkaline phosphatase value for OS (HR=1.04; 95% CI=1.00-1.07; p=0.015). Conclusion: This study demonstrates the prognostic significance of alkaline phosphatase and lactate dehydrogenase values in Japanese men with de novo metastatic hormone-sensitive prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85067537872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067537872&partnerID=8YFLogxK

U2 - 10.21873/anticanres.13457

DO - 10.21873/anticanres.13457

M3 - Article

C2 - 31177166

AN - SCOPUS:85067537872

VL - 39

SP - 3191

EP - 3195

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -